CLINICAL TRIALS PROFILE FOR XIFAXAN
✉ Email this page to a colleague
All Clinical Trials for XIFAXAN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00269399 ↗ | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Completed | Bausch Health Americas, Inc. | Phase 3 | 2005-12-01 | The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD). |
NCT00269399 ↗ | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2005-12-01 | The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD). |
NCT00577772 ↗ | Transit Time and Bacterial Overgrowth Using SmartPill Capsule | Terminated | The SmartPill Corporation | N/A | 2007-11-01 | The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth. |
NCT00577772 ↗ | Transit Time and Bacterial Overgrowth Using SmartPill Capsule | Terminated | Mayo Clinic | N/A | 2007-11-01 | The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth. |
NCT00603616 ↗ | Induction of Clinical Response Using Rifaximin in Crohn's Disease | Completed | Bausch Health Americas, Inc. | Phase 2 | 2008-11-01 | Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease. |
NCT00603616 ↗ | Induction of Clinical Response Using Rifaximin in Crohn's Disease | Completed | Valeant Pharmaceuticals International, Inc. | Phase 2 | 2008-11-01 | Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease. |
NCT00603616 ↗ | Induction of Clinical Response Using Rifaximin in Crohn's Disease | Completed | Scott Lee | Phase 2 | 2008-11-01 | Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XIFAXAN
Condition Name
Clinical Trial Locations for XIFAXAN
Trials by Country
Clinical Trial Progress for XIFAXAN
Clinical Trial Phase
Clinical Trial Sponsors for XIFAXAN
Sponsor Name